2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Motor Activity
14
Breast Neoplasms
11
Polycystic Ovary Syndrome
8
Obesity
8
Colorectal Neoplasms
8
Weight Loss
6
Neoplasms
6
Prostatic Neoplasms
5
Colonic Neoplasms
5
Endometrial Neoplasms
4
Multiple Endocrine Neoplasia Type 1
3
Recurrence
2
Pancreatic Neoplasms
2
Overweight
2
Ovarian Neoplasms
2
Malnutrition
2
Lymphoma, Follicular
2
Lymphoma
2
Lung Neoplasms
2
Carcinoma, Intraductal, Noninfiltrating
2
Body Weight Changes
2
Waldenstrom Macroglobulinemia
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Smoking Cessation
1
Smoking
1
Sexual Dysfunction, Physiological
1
Interventions
Cyclophosphamide
18
ofatumumab
14
fludarabine
12
Rituximab
11
ibrutinib
10
fludarabine phosphate
9
acalabrutinib
7
obinutuzumab
6
Lenalidomide
6
Bendamustine Hydrochloride
6
venetoclax
5
pirtobrutinib
4
Vincristine
4
Mesna
4
Melphalan
4
Immunotherapy, Adoptive
4
Whole-Body Irradiation
3
Mycophenolic Acid
3
Chlorambucil
3
Bortezomib
3
Alemtuzumab
3
spebrutinib
2
navitoclax
2
idelalisib
2
Tacrolimus
2
Tablets
2
Stem Cell Transplantation
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
KW-2478
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, B-Cell
×
Diet
×
Clear all
NCT07487428
2026-03-23
CLL-IMPACT
Technical University of Munich
Phase NA
Recruiting
50 enrolled